Cough Drops Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Setting up a cough drops unit in India layers on the FSSAI regime plus state-level factory and pollution touchpoints. For this project specifically (CapEx ₹1.8 crore - ₹13 crore, 3.2 - 4.9-year payback), KAMRIT maps these licence touchpoints:

• AGMARK certification for spices, edible oils, ghee, honey where claimed on-pack
• BIS mandatory list compliance (packaged water, infant formula, dairy products)
• Factory licence under the Factories Act 1948 (10+ workers with power threshold)
• State Pollution Control Board CTE and CTO (Red, Orange, Green category mapping)
• APEDA / Spices Board / Tea Board registration for export-bound supply
• GST registration above ₹40 lakh turnover, plus Shops & Establishments Act registration
• Cold-chain compliance for refrigerated SKUs, plus traceability under FSSAI MoFPI norms

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The cough drops and throat lozenges segment sits at the intersection of the pharmaceutical formulations industry and the confectionery sector, creating a unique dual classification under India's regulatory and tax frameworks. The broader cold, cough, and sore throat remedies market, of which throat lozenges are a key component, was valued at USD 45,300.1 million in 2026 and is expected to grow to USD 56,500.2 million by 2033 at a 3.5% CAGR. The India-specific throat lozenges market alone is valued at USD 321.99 million in 2025 and forecast to reach USD 500.0 million by 2035, while the wider cough syrups and drops ecosystem is projected at USD 654.0 million over the same horizon.</p><p>India's domestic market currently operates at below 20% penetration, signaling substantial headroom for growth.

The country's pharmaceutical sector has attracted cumulative foreign direct investment equity inflows that reached notable levels from January 2000 to December 2024, reflecting strong global investor confidence. The sector's cost structure is characterized by raw materials accounting for 60% to 70% of total operating expenditures, utilities at 10% to 15%, with the remainder covering labor, packaging, and distribution. With gross profit margins of 50% to 65% and net profit margins of 15% to 25% for established over-the-counter brands, the sector offers attractive unit economics.

A standard 20-count bag of cough drops retails between USD 2.50 and USD 4.00, with a cost of goods sold of approximately USD 0.90 to USD 1.20 per pack.</p><p>The cough suppressant market in India adds further depth, valued at USD 6.01 billion in 2025 with a projected CAGR of 7.3% from 2025 to 2035, significantly outpacing the throat lozenges segment. Globally, the throat lozenges market is valued at USD 5.70 billion in 2025 and projected to reach USD 8.84 billion by 2034 at a 5.0% CAGR, with Asia Pacific commanding a 42.1% regional share, positioning India at the center of global growth.</p>

Project-specific demand drivers

• Rising organised retail penetration
• Premium-segment up-trade
• Quick-commerce delivery accelerating consumption
• FSSAI compliance lifting industry quality
• Export demand from GCC and SE Asia diaspora

<p>The manufacturing process for cough drops and throat lozenges follows a well-established but technically precise sequence that demands specialized equipment and process control. The core steps include mixing and dissolving of raw materials, cooking at temperatures between 140 degrees Celsius and 150 degrees Celsius, vacuum mass cooling and kneading to approximately 86 degrees Celsius, forming into individual lozenges, and final cooling and wrapping. Each stage requires precise temperature and timing control to achieve the correct texture, hardness, and dissolution profile.</p><p>Equipment selection and plant automation represent the most critical technology investment decisions.

Propack Technologies exemplifies advanced plant configuration with multi-phase mixing systems that integrate a premix vessel, a sugar melting vessel, and a main mixing vessel, all equipped with inline homogenizers capable of reducing particle sizes to deliver consistent product quality. The plant and machinery allocation typically consumes 30% to 45% of total capital expenditure for a new facility, underscoring the capital-intensive nature of technology infrastructure.</p><p>Active pharmaceutical ingredients and excipients form the technological heart of the formulation. Key inputs include natural menthol crystals with an assay minimum of 99% conforming to USP/IP/BP/EP standards, synthetic menthol, dextromethorphan, and guaifenesin.

Excipients and sweeteners encompass sugar, glucose syrup, honey, and flavorings such as peppermint oil, eucalyptus oil, lemon, and ginger. Specialized packaging materials are required to maintain product integrity, shelf life, and consumer convenience. The sourcing landscape features both domestic suppliers like Vinayak Ingredients (India) Private Limited and Bhagat Aromatics Limited, as well as import-dependent channels for specialized inputs where domestic supply falls short of demand.</p><p>Energy efficiency and sustainability mandates are increasingly shaping plant design.

Industry participants across pharmaceutical manufacturing are expected to comply with ISO 50001 (Energy Management Systems) standards and the Greenhouse Gas (GHG) Protocol covering Scopes 1, 2, and 3 emissions. Leading manufacturers have reported up to 30% reductions in thermal and process energy usage through upgraded equipment and process optimization, with net-zero operational carbon targets set for 2050. Smart manufacturing and automation technologies are being adopted to improve yield consistency, reduce waste, and lower per-unit production costs.</p>

KAMRIT recommends a Debt:Equity ratio of 65:35 for projects in the ₹6, 13 crore CapEx band and 55:45 for projects below ₹4 crore, reflecting the asset-backed nature of the facility and the working-capital intensity of inventory management in the FMCG channel. For the ₹6 crore mid-scale scenario, the means of finance break down as follows: term loan from State Bank of India (SBI) or HDFC Bank under their Food Processing Scheme at 9.5, 10.75% ROI, constituting approximately ₹3.6 crore; SIDBI's Food Processing Fund offering ₹1.2 crore at 8.75, 9.5% with a 7-year tenor; promoter equity at ₹1 crore; and a working-capital facility of ₹1.2 crore from the consortium banker's Cash Credit limit at MCLR + 75, 150 bps. PMEGP (Prime Minister's Employment Generation Programme) administered through KVIC is applicable for units below ₹2 crore with a project cost subsidy ceiling of ₹1 lakh per seat for general category and ₹1.5 lakh for SC/ST/Women, though the subsidy is released post-disbursement milestone and is not netted from the loan principal. CGTMSE (Credit Guarantee Fund Trust for Micro and Small Enterprises) cover is available for the term loan tranche, reducing the effective risk weight for the lending bank and enabling collateral-free borrowing up to ₹5 crore. State MSME schemes in Gujarat (Mudra Plus), Maharashtra (Maharashtra State Innovation Society), and Himachal Pradesh (HIMCARE food processing subsidy) offer additional top-up grants of 5, 10% of CapEx, and KAMRIT's financial structuring team coordinates applications concurrently with the bank loan process. Working-capital cycle is estimated at 48, 55 days: raw material inventory (12 days at 18, 20 days' stock), production cycle (5, 7 days), finished goods (15, 18 days), and trade receivables (20, 22 days against kirana distributors, 7, 10 days against modern trade). Sensitivity analysis on the ₹6 crore base case shows EBITDA margin ranging from 18.2% at 60% capacity utilisation to 26.8% at 90% utilisation, with the payback period ranging from 4.9 years (60% utilisation) to 3.2 years (85% utilisation and above).

<p>Capital expenditure requirements for establishing a competitive cough drops plant are substantial and present a significant entry barrier. A small-scale or domestic-focused plant setup costs between INR 5 crores and INR 15 crores, equivalent to USD 600,000 to USD 1.8 million, while a mid-scale export-ready facility requires INR 50 crores to INR 80 crores, or USD 6 million to USD 9.5 million. Land acquisition, building construction, plant and machinery, and working capital requirements must all be financed simultaneously, and delays in project commissioning can strain cash reserves before revenue generation begins.

Operating costs are front-loaded, with raw materials alone representing 60% to 70% of total operating expenditures, making new entrants vulnerable to input price volatility.</p><p>Regulatory compliance represents a continuous and non-trivial risk. The CDSCO enforces Schedule M good manufacturing practices, and non-compliance can result in production shutdowns, product recalls, and reputational damage. A real-world example underscores this risk: Xiamen Kang Zhongyuan Biotechnology Co., Ltd. in Xiamen, China, underwent a facility inspection on August 15, 2025, resulting in an FDA Class II classification on April 10, 2026, and a recall initiation on March 20, 2026 that affected 15 nationwide cough drop and throat lozenge products across multiple brand labels including Exchange Select, Caring Mill, Discount Drug Mart Food Market, and MGC.

Such regulatory actions can devastate brand equity and market position, emphasizing the critical importance of investing in quality assurance and compliance infrastructure from day one.</p><p>Market concentration risk is significant, as the market is dominated by well-established multinational players with decades of brand equity, massive distribution networks, and deep financial resources. Reckitt Benckiser, Procter & Gamble, Pfizer, and Haleon collectively control a substantial share of organized retail channels, and their marketing budgets dwarf those available to new entrants. The organized versus unorganized market segmentation means that new domestic players may be confined to regional or price-sensitive segments unless they invest heavily in brand building and distribution scale.

Prason Foods operates at only 60% of its 2 million lozenges per day capacity despite holding GMP and ISO 9001-2015 certifications, illustrating that capacity utilization challenges are real even for compliant, certified operators.</p><p>Import dependency for key inputs poses supply chain risk. Domestic demand for specialized active pharmaceutical ingredients frequently surpasses local supply, requiring imports that are subject to foreign exchange fluctuations, shipping delays, and international regulatory changes. Natural menthol pricing varies based on origin, quality, and market conditions, with ex-Moradabad pricing reflecting domestic market dynamics that can shift with harvest cycles, monsoon conditions, and export demand from international buyers.

Energy cost inflation and potential utility supply disruptions in manufacturing hubs could further compress already narrow operating margins, particularly for smaller operators without the hedging capabilities of multinational companies.</p>